Clinical Trial Update: Belatacept With Early Steroid Withdrawal rATG and Everolimus in Renal Transplantation (BETTER Trial) [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating belatacept with early steroid withdrawal, rATG, and everolimus in kidney transplant patients with rejection risk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Transplant Rejection

Drugs mentioned

• Everolimus (everolimus)
• belatacept (belatacept)
• rATG (rabbit anti-thymocyte globulin)

Snippet

Sponsor: University of Cincinnati | Conditions: Kidney Transplant Rejection | Phase 4 | Status: UNKNOWN